- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659031
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
November 27, 2023 updated by: Abcuro, Inc.
A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ken Cooper
- Phone Number: 610-310-2271
- Email: Ken.cooper@abcuro.com
Study Locations
-
-
-
Herston, Australia
- Royal Brisbane
-
Perth, Australia
- Perron Institute
-
Sydney, Australia
- Royal North Shore Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Diagnosis of either clinico-pathologically defined IBM, clinically defined IBM, or probable IBM according to the European Neuromuscular Center (ENMC) IBM 2011
- Able to arise from a chair (with or without armrests) without support from another person or device
- Able to ambulate at least 20 feet / 6 meters with or without assistive device
Exclusion Criteria:
- Taking > 7.5 mg prednisolone (or equivalent) or on intravenous immunoglobulin (IVIg) or other immunosuppressants within the last 3 months. Topical, nasal, and ocular corticosteroids are allowed unless they are being widely applied or the severity of the underlying condition makes them unsuitable in the Investigator's opinion. Local steroid injections are allowed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort D1
Single Dose 0.1 mg / kg ABC008
|
ABC008
|
Experimental: Cohort D2
Single Dose 0.5 mg / kg ABC008
|
ABC008
|
Experimental: Cohort D3
Single Dose 2.0 mg / kg ABC008
|
ABC008
|
Experimental: Cohort D4
Single Dose 5.0 mg / kg ABC008
|
ABC008
|
Experimental: Cohort D5
X.X mg / kg ABC008
|
ABC008
|
Experimental: Cohort 6
Single 2.0 mg / kg ABC008
|
ABC008
|
Experimental: MAD Phase Cohort 1
Multiple Dose 0.1 mg / kg ABC008 every 8 weeks
|
ABC008
|
Experimental: MAD Phase Cohort 2
Multiple Dose 0.5 mg / kg ABC008 every 8 weeks
|
ABC008
|
Experimental: MAD Phase Cohort 3
Multiple Dose 2.0 mg / kg ABC008 every 8 weeks
|
ABC008
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Safety and Tolerability
Time Frame: Through Study Completion an average of 28 weeks for SAD (Single Ascending Dose) phase and 52 weeks for MAD (Multiple Ascending Dose) phase]
|
Characterize the safety and tolerability profile of single (SAD) and multiple (MAD) escalating dose levels of ABC008 in IBM when administered subcutaneously (SC) as measured by the number and severity of treatment emergent adverse events, serious adverse events, and adverse events of special interest, number of dose limiting toxicities.
|
Through Study Completion an average of 28 weeks for SAD (Single Ascending Dose) phase and 52 weeks for MAD (Multiple Ascending Dose) phase]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of peak serum concentration (Cmax)
Time Frame: Day 1 and throughout the 24 weeks of follow up
|
Assess the peak serum concentration (Cmax) of a single dose of ABC008
|
Day 1 and throughout the 24 weeks of follow up
|
Assessment of time to peak serum concentration (Tmax)
Time Frame: Day 1 and throughout the 24 weeks of follow up
|
Assess the time to peak serum concentration (Tmax) of a single dose of ABC008
|
Day 1 and throughout the 24 weeks of follow up
|
Assessment of terminal half-life (t½)
Time Frame: Day 1
|
Assess the terminal half-life (t½) of ABC008
|
Day 1
|
Assessment of area under the concentration versus time curve from time zero to 24 hours post-dose (AUC0-24hr)
Time Frame: Day 1
|
Assess the area under the concentration versus time curve of a single dose of ABC008 from time zero to 24 hours post-dose (AUC0-24hr)
|
Day 1
|
Assessment of apparent clearance (CL/F)
Time Frame: Day 1 and throughout the 24 weeks of follow up
|
Assessment of apparent clearance (CL/F) of a single dose of ABC008
|
Day 1 and throughout the 24 weeks of follow up
|
Assessment of apparent volume of distribution (Vz/F)
Time Frame: Day 1 and throughout the 24 weeks of follow up
|
Assessment of apparent volume of distribution (Vz/F) of a single dose of ABC008
|
Day 1 and throughout the 24 weeks of follow up
|
Characterization of changes in KLRG1 expressing lymphocytes
Time Frame: Day 1 and throughout the 24 weeks of follow up
|
Characterize changes in KLRG1 expressing lymphocytes
|
Day 1 and throughout the 24 weeks of follow up
|
Qualitative assessment of [ 89Zr]Zr-Df-crefmirlimab
Time Frame: [Through Study Completion, avg. 48 weeks
|
Qualitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites as determined by using a visual scoring (VS) system for the time point assessed, the possible scores VS1-VS5
|
[Through Study Completion, avg. 48 weeks
|
Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in skeletal muscle
Time Frame: [Through Study Completion, avg. 48 weeks
|
Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in skeletal muscle; Pattern(s) of absolute and relative changes in uptake within various skeletal muscle groups; Homogenous/diffuse, Focal, Mixed, Other
|
[Through Study Completion, avg. 48 weeks
|
Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in lymphoid organs
Time Frame: [Through Study Completion, avg. 48 weeks
|
Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in lymphoid organs; Uptake and relative changes in uptake within lymphoid tissue including spleen and lymph nodes as well as other T-cell rich tissues such as bone marrow
|
[Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab pre and post dosing of ABC008
Time Frame: [Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake and relative changes in uptake within inflamed muscle tissue through Positron Emission Tomography (PET)/computed tomography (CT) imaging pre- and post-dosing with ABC008
|
[Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis peak (SUVpeak)
Time Frame: [Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis peak (SUVpeak)
|
[Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis mean (SUVmean)
Time Frame: [Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis mean (SUVmean)
|
[Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis SUV of diseased muscle
Time Frame: [Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis SUV of diseased muscle
|
[Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis SUV reference tissue
Time Frame: [Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis SUV reference tissue
|
[Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis maximum (SUVmax)
Time Frame: [Through Study Completion, avg. 48 weeks
|
Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis maximum (SUVmax)
|
[Through Study Completion, avg. 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 25, 2021
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
November 25, 2020
First Submitted That Met QC Criteria
December 2, 2020
First Posted (Actual)
December 9, 2020
Study Record Updates
Last Update Posted (Actual)
November 28, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABC008-IBM-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inclusion Body Myositis
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body Myositis (sIBM)United States
-
University of Kansas Medical CenterCompletedInclusion Body Myositis | Sporadic Inclusion Body MyositisUnited States
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body MyositisUnited States
-
Institut National de la Santé Et de la Recherche...CompletedInclusion Body Myositis (IBM)France
-
La-ser Europe LimitedUnknownSporadic Inclusion Body Myositis
-
University of Southern DenmarkOdense University HospitalCompleted
-
Regeneron PharmaceuticalsWithdrawnSporadic Inclusion Body Myositis
-
Phoenix Neurological Associates, LTDUnknown
-
University of California, IrvineNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Active, not recruitingInclusion Body Myositis | Sporadic Inclusion Body MyositisUnited States
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body MyositisUnited States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Clinical Trials on ABC008
-
Abcuro, Inc.RecruitingT-cell Large Granular Lymphocytic LeukemiaUnited States
-
Abcuro, Inc.Syneos HealthActive, not recruitingInclusion Body MyositisUnited States, Australia, Belgium, France, Canada, Germany, United Kingdom